Meissa Vaccines, a South San Francisco, CA-based biotechnology startup developing vaccines to prevent viral respiratory infections, received a seed funding from FundRx, an innovative healthcare & life sciences venture capital platform based in New York City.
The amount of the deal was not disclosed.
The company intends to use the funds for an investigational new drug (IND) filing for its lead asset, a live attenuated RSV vaccine candidate for infants.
Led by Dr. Martin Moore, Chief Executive Officer, Meissa Vaccines is focused on the advancement of vaccines for respiratory syncytial virus (RSV, the largest unmet respiratory medical need in pediatrics) and rhinovirus (the leading cause of infectious disease worldwide).
The technology is sourced from Dr. Moore’s laboratory at Emory University. Dr. Moore, together with Dr. Roderick Tang, a developer of viral vaccines, are co-founders of Meissa.
They are supported by a team with experience in conducting vaccine clinical trials.
Meissa Vaccines is a resident company of Johnson & Johnson Innovation, JLABS in South San Francisco (JLABS @SSF).